T. Rowe Price Investment Management, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 25,644 shares of MDGL stock, worth $5.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,644
Previous 42,986
40.34%
Holding current value
$5.3 Million
Previous $11.5 Million
37.41%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding MDGL
# of Institutions
299Shares Held
22MCall Options Held
757KPut Options Held
370K-
Janus Henderson Group PLC London, X02.49MShares$514 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.06MShares$425 Million7.86% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$408 Million7.35% of portfolio
-
Rtw Investments, LP New York, NY1.92MShares$396 Million8.96% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.85MShares$382 Million39.74% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $3.54B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...